Despite widespread interest in developing small molecules used as P-gp inhibitors to combat MDR in cancer chemotherapy, the vast majority of previously discovered inhibitors have failed to pass Food and Drug Administration (FDA)-approved clinical-phase trials [79]. This evidence concerns the gene PGP and cancer.